GSK plc 每股年股息為 0.596,收益率為 0.00%。股息每 每季度 支付,最後除權日為 Nov 13, 2025。
股息收益率
年度股息
除息日
0.00%
$0.596
Nov 13, 2025
付款頻率
派息比例
每季度
0.00%
股利歷史
除息日
現金金額
記錄日期
付款日
Nov 13, 2025
$0.16
Nov 14, 2025
Jan 8, 2026
Aug 14, 2025
$0.16
Aug 15, 2025
Oct 9, 2025
May 15, 2025
$0.16
May 16, 2025
Jul 10, 2025
Feb 20, 2025
$0.16
Feb 21, 2025
Apr 10, 2025
Nov 14, 2024
$0.15
Nov 15, 2024
Jan 9, 2025
Aug 15, 2024
$0.15
Aug 16, 2024
Oct 10, 2024
股利圖表
GLAXF 股利
GLAXF 股息增長(年增率)
關鍵數據
前收市價
$29.55
開盤價
$30.15
當日範圍
$30.15 - $30.15
52週區間
$15.54 - $30.15
交易量
517
平均成交量
2.1K
每股盈餘 (TTM)
1.78
股息收益率
--
市值
$60.8B
什麼是 GLAXF?
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.